The significant quality of life burden associated with symptoms of itching and/or skin pain in patients with atopic dermatitis (AD) may warrant alternate approaches to address unmet needs. Symptoms of ...

The panel delves into the most challenging symptoms of atopic dermatitis (AD), maps out the patient journey, and highlights crucial factors in effectively managing itch and other AD-related symptoms.

Johnson & Johnson announced it will pay $1.25 billion to buy an experimental bispecific antibody targeting atopic dermatitis (AD) from Numab Therapeutics. The all-cash deal, which was announced ...

Topical ruxolitinib appears to quickly relieve itch in Black patients with atopic dermatitis (AD), an industry-sponsored analysis of pooled data from two studies suggests. "Ruxolitinib cream ...

– Adult patients with atopic dermatitis treated with Opzelura experienced rapid and substantial improvement in itch, which was sustained through Day 28 Results showed that patients with AD treated ...

Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...

"Galderma’s Nemluvio shows itch reduction in 48 hours" was originally created and published by Clinical Trials Arena, a ...

In patients with moderate to severe atopic dermatitis (AD), abrocitinib, an oral JAK inhibitor, relieved itch more quickly than the monoclonal antibody dupilumab (Dupixent), in a multicenter ...

Nemolizumab rapidly relieves itch and sleep disturbance among patients with moderate-to-severe atopic dermatitis (AD) and ...

A recently approved injectable eczema drug provides quick itch relief to patients with the maddening skin disease, a new ...